Menu

Menu

News & Updates

2023

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) As 2022 comes to a close, I would like to highlight some our many accomplishments achieved this year and also to respond to the multiple queries regarding future business strategy and planning that we have received.
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) As 2022 comes to a close, I would like to...
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) As 2022 comes to a close, I would like to...
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 14, 2022
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 14, 2022
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 14, 2022
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
Read more
2022

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) As 2022 comes to a close, I would like to highlight some our many accomplishments achieved this year and also to respond to the multiple queries regarding future business strategy and planning that we have received.
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) As 2022 comes to a close, I would like to...
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) As 2022 comes to a close, I would like to...
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 14, 2022
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 14, 2022
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 14, 2022
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
Read more

Source : Regen BioPharma, Inc

REGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER
Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP): First of all I would like to wish all our shareholders a happy holiday season. It has been a…
Read more

Source : Regen BioPharma, Inc

REGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER
Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP): First of all I would like to wish all our shareholders a happy holiday season. It has...
Read more

Source : Regen BioPharma, Inc

REGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER
Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP): First of all I would like to wish all our shareholders a happy holiday season. It has...
Read more

Source : Regen BioPharma, Inc.

Regen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized Medicine
Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP) is currently completing a strategic analysis of its next 5 years of growth. As part of this…
Read more

Source : Regen BioPharma, Inc.

Regen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized Medicine
Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP) is currently completing a strategic analysis of its next 5 years of growth. As part of this…
Read more

Source : Regen BioPharma, Inc.

Regen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized Medicine
Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP) is currently completing a strategic analysis of its next 5 years of growth. As part of this…
Read more

Source : Regen BioPharma, Inc.

Regen BioPharma, Inc. Discovers Fundamental Role of NR2F6 in Production of Malignant Blood Vessels
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today new data demonstrating that suppression of NR2F6 using patent-pending…
Read more

Source : Regen BioPharma, Inc.

Regen BioPharma, Inc. Discovers Fundamental Role of NR2F6 in Production of Malignant Blood Vessels
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today new data demonstrating that suppression of NR2F6 using patent-pending…
Read more

Source : Regen BioPharma, Inc.

Regen BioPharma, Inc. Discovers Fundamental Role of NR2F6 in Production of Malignant Blood Vessels
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today new data demonstrating that suppression of NR2F6 using patent-pending…
Read more

Source : Regen BioPharma Inc.

Regen BioPharma Successfully Treats Rheumatoid Arthritis Using Cannabidiol (CBD) Based Immune Modulatory Treatments
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today positive data demonstrating that its novel cannabidiol-based therapeutic…
Read more

Source : Regen BioPharma Inc.

Regen BioPharma Successfully Treats Rheumatoid Arthritis Using Cannabidiol (CBD) Based Immune Modulatory Treatments
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today positive data demonstrating that its novel cannabidiol-based therapeutic…
Read more

Source : Regen BioPharma Inc.

Regen BioPharma Successfully Treats Rheumatoid Arthritis Using Cannabidiol (CBD) Based Immune Modulatory Treatments
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today positive data demonstrating that its novel cannabidiol-based therapeutic…
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. Reports Additional New NR2F6 Small Molecule Inhibitors
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) researchers have identified three new series of small molecule drugs that inhibit NR2F6,…
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. Reports Additional New NR2F6 Small Molecule Inhibitors
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) researchers have identified three new series of small molecule drugs that inhibit NR2F6,…
Read more

Source : Regen BioPharma Inc.

Regen BioPharma, Inc. Reports Additional New NR2F6 Small Molecule Inhibitors
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) researchers have identified three new series of small molecule drugs that inhibit NR2F6,…
Read more

Source : Regen BioPharma, Inc.

Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that its lead NR2F6 small molecule agonist,…
Read more

Source : Regen BioPharma, Inc.

Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that its lead NR2F6 small molecule agonist,…
Read more

Source : Regen BioPharma, Inc.

Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that its lead NR2F6 small molecule agonist,…
Read more

Source : PRNewswire

Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has initiated in vivo and ex vivo assessments to determine the effects of some of the Company’s NR2F6 small molecule agonists in live rats and in tissues derived from humans and rats. Key attributes that are being measured include pH, plasma and liver microsomal stability, along with...
Read more

Source : PRNewswire

Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has initiated in vivo and ex vivo assessments to determine the effects of some of the Company’s...
Read more

Source : PRNewswire

Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has initiated in vivo and ex vivo assessments to determine the effects of some of the Company’s...
Read more

Source : PRNewswire

Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6
18 months ago, Regen BioPharma Inc. (OTCQB: RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor,...
Read more

Source : PRNewswire

Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6
18 months ago, Regen BioPharma Inc. (OTCQB: RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear...
Read more

Source : PRNewswire

Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6
18 months ago, Regen BioPharma Inc. (OTCQB: RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear...
Read more

Source : PR NEWSWIRE

December 16, 2016 SOURCE: PR NEWSWIRE
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact with the Company’s newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis...
Read more

Source : PR NEWSWIRE

December 16, 2016 SOURCE: PR NEWSWIRE
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact...
Read more

Source : PR NEWSWIRE

December 16, 2016 SOURCE: PR NEWSWIRE
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact...
Read more

Source : REGEN BIOPHARMA INC.

December 16, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
Read more

Source : REGEN BIOPHARMA INC.

December 16, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
Read more

Source : REGEN BIOPHARMA INC.

December 16, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
Read more

Source : REGEN BIOPHARMA INC.

December 15, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate. Company to initiate Phase I Clinical Trial for IMmune Modulatory Personalized Cell Therapy in Treatment of Aplastic Anemia.
Read more

Source : REGEN BIOPHARMA INC.

December 15, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate. Company to initiate Phase I Clinical Trial for IMmune Modulatory Personalized Cell Therapy...
Read more

Source : REGEN BIOPHARMA INC.

December 15, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate. Company to initiate Phase I Clinical Trial for IMmune Modulatory Personalized Cell Therapy...
Read more

Source : REGEN BIOPHARMA INC.

December 1, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc.  Attracts Top Researchers to Scientific Advisory Board.
Read more

Source : REGEN BIOPHARMA INC.

December 1, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc.  Attracts Top Researchers to Scientific Advisory Board.
Read more

Source : REGEN BIOPHARMA INC.

December 1, 2015 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc.  Attracts Top Researchers to Scientific Advisory Board.
Read more

Source : Regen BioPharma, Inc.

December 11, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Presented Novel Therapeutic Target for Leukemia and Myelodysplastic Syndrome at the American Society of Hematology Annual Meeting 
Read more

Source : Regen BioPharma, Inc.

December 11, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Presented Novel Therapeutic Target for Leukemia and Myelodysplastic Syndrome at the American Society of Hematology Annual Meeting 
Read more

Source : Regen BioPharma, Inc.

December 11, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Presented Novel Therapeutic Target for Leukemia and Myelodysplastic Syndrome at the American Society of Hematology Annual Meeting 
Read more

Source : Regen BioPharma, Inc.

December 1, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Scheduled to Make Presentation at American Society for Hematology’s 56th Annual Meeting in San Francisco December 6th – 9th 
Read more

Source : Regen BioPharma, Inc.

December 1, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Scheduled to Make Presentation at American Society for Hematology’s 56th Annual Meeting in San Francisco December 6th – 9th 
Read more

Source : Regen BioPharma, Inc.

December 1, 2014 | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Scheduled to Make Presentation at American Society for Hematology’s 56th Annual Meeting in San Francisco December 6th – 9th 
Read more

Source : Regen BioPharma, Inc.

December 11, 2013 09:35 ET | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Announces HemaXellerate I™ Efficacy Data in Animal Model of Aplastic Anemia
Read more

Source : Regen BioPharma, Inc.

December 11, 2013 09:35 ET | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Announces HemaXellerate I™ Efficacy Data in Animal Model of Aplastic Anemia
Read more

Source : Regen BioPharma, Inc.

December 11, 2013 09:35 ET | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Announces HemaXellerate I™ Efficacy Data in Animal Model of Aplastic Anemia
Read more

Source : Regen BioPharma, Inc.

October 31, 2013 11:35 ET | SOURCE: Regen BioPharma, Inc.
Bio-Matrix Scientific Group’s Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I
Read more

Source : Regen BioPharma, Inc.

October 31, 2013 11:35 ET | SOURCE: Regen BioPharma, Inc.
Bio-Matrix Scientific Group’s Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I
Read more

Source : Regen BioPharma, Inc.

October 31, 2013 11:35 ET | SOURCE: Regen BioPharma, Inc.
Bio-Matrix Scientific Group’s Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I
Read more

Source : Regen BioPharma, Inc.

November 19, 2012 08:30 ET | SOURCE: Regen BioPharma, Inc.
Bio-Matrix’ Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate™ Cell Therapy
Read more

Source : Regen BioPharma, Inc.

November 19, 2012 08:30 ET | SOURCE: Regen BioPharma, Inc.
Bio-Matrix’ Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate™ Cell Therapy
Read more

Source : Regen BioPharma, Inc.

November 19, 2012 08:30 ET | SOURCE: Regen BioPharma, Inc.
Bio-Matrix’ Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate™ Cell Therapy
Read more

Source : Regen BioPharma, Inc.

October 29, 2012 10:30 ET | SOURCE: Regen BioPharma, Inc.
Read more

Source : Regen BioPharma, Inc.

October 29, 2012 10:30 ET | SOURCE: Regen BioPharma, Inc.
Read more

Source : Regen BioPharma, Inc.

October 29, 2012 10:30 ET | SOURCE: Regen BioPharma, Inc.
Read more

An overview of Regen BioPharma

Our management, scientific advisory board and intellectual property

Details around our intellectual property and its development

Our public filing and stock information

Our press releases and upcoming events

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Investor Relations

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Company News

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
Twitter

What we do

Product Pipeline

Inverstor Relations

News & Updates

Management Team and Scientific Advisory Board

Careers

Contact Us

DuraCAR

KimerApt

HemaXellerate

dCellVax

tCellVax

DiffronC

Regulatory Filings

Featured News

News and Updates

Twitter
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases

An overview of Regen BioPharma

Our management, scientific advisory board and intellectual property

Details around our intellectual property and its development

Our public filing and stock information

Our press releases and upcoming events

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Investor Relations

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Company News

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
Twitter

What we do

Product Pipeline

Inverstor Relations

News & Updates

Management Team and Scientific Advisory Board

Careers

Contact Us

DuraCAR

KimerApt

HemaXellerate

dCellVax

tCellVax

DiffronC

Regulatory Filings

Featured News

News and Updates

Twitter
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases